Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $16.19

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $16.19, but opened at $15.52. Y-mAbs Therapeutics shares last traded at $14.99, with a volume of 58,710 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on YMAB shares. HC Wainwright boosted their target price on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Wednesday, March 6th. BMO Capital Markets increased their target price on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an "outperform" rating in a research report on Monday, March 4th. Canaccord Genuity Group lifted their price target on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a "buy" rating in a report on Monday, March 4th. Finally, Wedbush reiterated an "outperform" rating and set a $18.00 price objective (up previously from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $16.57.

Y-mAbs Therapeutics Price Performance

The stock's fifty day simple moving average is $15.12 and its 200-day simple moving average is $9.31. The firm has a market cap of $646.19 million, a PE ratio of -30.06 and a beta of 0.74.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.17. Y-mAbs Therapeutics had a negative return on equity of 20.72% and a negative net margin of 25.26%. The company had revenue of $23.36 million during the quarter, compared to analyst estimates of $21.72 million. Analysts expect that Y-mAbs Therapeutics, Inc. will post -0.43 earnings per share for the current year.

Insider Transactions at Y-mAbs Therapeutics

In related news, SVP Vignesh Rajah sold 1,711 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $16.53, for a total value of $28,282.83. Following the transaction, the senior vice president now owns 33,889 shares in the company, valued at approximately $560,185.17. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 21.50% of the company's stock.

Institutional Trading of Y-mAbs Therapeutics

Several large investors have recently made changes to their positions in YMAB. Vanguard Group Inc. raised its holdings in shares of Y-mAbs Therapeutics by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 2,244,238 shares of the company's stock worth $15,306,000 after purchasing an additional 12,330 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Y-mAbs Therapeutics by 2.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 397,951 shares of the company's stock worth $2,714,000 after purchasing an additional 8,604 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Y-mAbs Therapeutics by 6.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,501 shares of the company's stock valued at $133,000 after buying an additional 1,219 shares during the last quarter. Barclays PLC lifted its holdings in shares of Y-mAbs Therapeutics by 700.3% in the 4th quarter. Barclays PLC now owns 50,437 shares of the company's stock valued at $344,000 after buying an additional 44,135 shares during the period. Finally, Nuveen Asset Management LLC boosted its stake in shares of Y-mAbs Therapeutics by 11.6% in the fourth quarter. Nuveen Asset Management LLC now owns 399,940 shares of the company's stock worth $2,728,000 after buying an additional 41,541 shares during the last quarter. 70.85% of the stock is owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.